Premium
Analysis of Androgen‐and Progestin Receptors in Human Endometrial Carcinomas
Author(s) -
Kato Junzo,
Onouchi Tsuneko,
Ueda Kuniaki,
Arai Kiyoshi,
Okinaga Shoichi,
Kubo Hisamitsu,
Mori Hiroyuki,
Seto Terukazu
Publication year - 1982
Publication title -
asia‐oceania journal of obstetrics and gynaecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.597
H-Index - 50
eISSN - 1447-0756
pISSN - 0389-2328
DOI - 10.1111/j.1447-0756.1982.tb00564.x
Subject(s) - androgen receptor , androgen , progestin , endocrinology , medicine , receptor , chemistry , biology , cancer research , hormone , cancer , prostate cancer
Androgen‐binding components labeled with a tritiated synthetic androgen, methyltrienolone(R1881) were analysed in human endometrial carcinoma cytosols. Tritiated R1881 binding consists of 3 components; high‐affinity, low capacity androgen binding (androgen receptor), possible progestin receptor and non‐specific androgen binding. The existence of androgen receptor in the tumor suggests a direct effect of androgen in endometrial carcinoma, possibly, through its interaction with the androgen receptor. Androgen‐ and progestin receptors were further measured in the cytosols of 20 endometrial carcinomas from 19 non‐treated patients. The concentrations of the androgen receptors in the endometrial carcinomas were, in decreasing order; highly differentiated [21.5 + 5.4(SEM) fmoles/mg protein, N=10], moderately differentiated [3.4 + 2.7, N=3] and poorly differentiated tumors [2.5 + 1.4, N=7]. The concentrations of progestin receptors in the highly differentiated, moderately differentiated and poorly differentiated tumors were 291 + 79.7 (N=10), 52.6 + 34.1(3) and 14.7 + 6.8(7), respectively. Androgen‐ and progestin receptors in endometrial carcinomas would appear to correlate with histologic grade of differentiation of the tumor.